Phathom Pharmaceuticals (PHAT) announced a partnership with actor, comedian, and author Kenan Thompson, best known as the longest-running cast member on Saturday Night Live. For the first time ever, Thompson is publicly speaking out about his experience with GERD as part of the GERD IS NO JOKE campaign to raise awareness about the condition and encourage others to talk with their doctor about treatment options. Thompson, who has been diagnosed with the most common form of GERD, called Non-Erosive GERD, found heartburn relief with VOQUEZNA after struggling with other treatments. VOQUEZNA is the first and only treatment of its kind approved by the U.S. Food and Drug Administration to help manage his condition. VOQUEZNA is approved for use in adults for the relief of heartburn associated with Non-Erosive GERD and for the treatment of all severities of Erosive Esophagitis, commonly referred to as Erosive GERD, and relief of related heartburn.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Biotech Alert: Searches spiking for these stocks today
- Phathom Pharmaceuticals: Favorable Risk/Reward Profile Amid Challenges and Growth Opportunities
- Phathom Pharmaceuticals price target lowered to $13 from $17 at Jefferies
- Closing Bell Movers: Harrow spikes 24% on revenue beat, leverage update
- Phathom Pharmaceuticals director buys $44.2K shares of common stock